Literature DB >> 24725684

Acceler-dated fractionation: the end of the era of the large, "one size fits all" trial for locally advanced head and neck cancer.

Quynh-Thu Le1, Mitchell Machtay2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24725684      PMCID： PMC3986724          DOI： 10.1016/j.ijrobp.2014.01.045

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  12 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.

Authors:  Jean Bourhis; Christian Sire; Pierre Graff; Vincent Grégoire; Philippe Maingon; Gilles Calais; Bernard Gery; Laurent Martin; Marc Alfonsi; Patrick Desprez; Thierry Pignon; Etienne Bardet; Michel Rives; Lionel Geoffrois; Nicolas Daly-Schveitzer; Sok Sen; Claude Tuchais; Olivier Dupuis; Stéphane Guerif; Michel Lapeyre; Véronique Favrel; Marc Hamoir; Antoine Lusinchi; Stéphane Temam; Antonella Pinna; Yun Gan Tao; Pierre Blanchard; Anne Aupérin
Journal:  Lancet Oncol       Date:  2012-01-18       Impact factor: 41.316

3.  Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.

Authors:  Volker Budach; Martin Stuschke; Wilfried Budach; Michael Baumann; Dirk Geismar; Gerhard Grabenbauer; Ingrid Lammert; Klaus Jahnke; Georg Stueben; Thomas Herrmann; Michael Bamberg; Peter Wust; Wolfgang Hinkelbein; Klaus-Dieter Wernecke
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 4.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

5.  Tailored immunotherapy for HPV positive head and neck squamous cell cancer.

Authors:  Neil Gildener-Leapman; John Lee; Robert L Ferris
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

6.  Immunologic correlates of the abscopal effect in a patient with melanoma.

Authors:  Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

Review 7.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Authors:  Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

8.  Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Johan W Molling; Jacqueline A E Langius; Johannes A Langendijk; C René Leemans; Hetty J Bontkes; Hans J J van der Vliet; B Mary E von Blomberg; Rik J Scheper; Alfons J M van den Eertwegh
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

9.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

10.  Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.

Authors:  Maura L Gillison; Qiang Zhang; Richard Jordan; Weihong Xiao; William H Westra; Andy Trotti; Sharon Spencer; Jonathan Harris; Christine H Chung; K Kian Ang
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544
View more
  1 in total

1.  Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma.

Authors:  Evangelia Katsoulakis; Yao Yu; Aditya P Apte; Jonathan E Leeman; Nora Katabi; Luc Morris; Joseph O Deasy; Timothy A Chan; Nancy Y Lee; Nadeem Riaz; Vaios Hatzoglou; Jung Hun Oh
Journal:  Oral Oncol       Date:  2020-06-30       Impact factor: 5.337
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.